Cardiology Today Current Issue
The following articles appeared in the print edition of Cardiology Today.
Table of Contents
- Migraine and CVD: A call for greater awareness
-
- QTFactors.org: A companion database for use with QTdrugs.org Klaus Romero, MS, MD; Tyler Gallo, PharmD; C. Will Heise, MD; Raymond L. Woosley, MD, PhD; R. David Woosley, MPH
- Antidote for certain direct oral anticoagulants receives FDA approval
- FDA advisory committees back CV safety of celecoxib
- FDA panel supports approval of volanesorsen for familial chylomicronemia syndrome
- Ambulatory BP measurements strong predictors of mortality
- CMS to cover MRIs for patients with pacemakers, ICDs
- Disparities in CVD burden persist among US states
- Dual antithrombotic therapy safer than triple therapy in AF after PCI
-
- FDA analysis: Women underrepresented in HF, CAD, ACS trials
- High-intensity statin therapy less likely in women after MI
- High-sensitivity troponin T levels detect low-risk patients
- Moderate to vigorous physical activity benefits reflex control of BP during pregnancy
- Alternative antibiotic strategy modestly improves cardiac device infection rate
- Botulinum toxin suppression of AF maintained at 3 years
- CABANA: Ablation an ‘acceptable treatment strategy’ for AF
- CV risk increases with hormone therapy in transgender patients
-
- HRS: How to counsel patients on cardiac device cybersecurity
- Outcomes worse with delayed discharge after transfemoral TAVR
- PROGRESS CTO registry highlights feasibility of hybrid approach at experienced centers
- US ranking for heart transplant candidates may prompt overtreatment
- At Issue: CABANA sparks debate over appropriateness of ablation in AF
- Cardiology Today honors Next Gen Innovators at ACC 2018
- Trial Scorecard: CABANA
- Trial Scorecard: FIX-HF-5C
-
- Trial Scorecard: KP-RHYTHM
- Trial Scorecard: NAVIGATE ESUS
- Trial Scorecard: PADIT
- Trial Scorecard: POINT
- Trial Scorecard: PROGRESS CTO
- Trial Scorecard: TASMINH4